from an Ebola infection he got while working in Liberia, he called his wife to say goodbye.
As the world now shelters in place with millions infected from the novel coronavirus, the question is, did we learn enough from Ebola to do better this time around? Researchers shouldn't be "doggedly insisting on gold standards that were developed for different settings and purposes," they wrote along with more than a dozen other expertsThe debate slogged on, even as Ebola cases began to fall. By February 2015, half a year after Brantly's recovery, the US National Institutes of Health had started a randomized controlled trial of ZMapp in the US and Liberia.
It's been about four months since the world saw the first cases of COVID-19, the disease caused by the coronavirus. And a swarm of research activity has so far led to almost no meaningful findings on a treatment. Most coronavirus drug trials fall short of this level of rigor. About 20% of studies that have finished or are now signing up patients meet this bar, as do 40% of trials planned to start soon, Ann Meeker-O'Connell, a vice president at Vertex Pharmaceuticals, said on a recent webinar.
Cox is now a vice president at the biotech company Regeneron, where he's making the same argument for COVID-19: If we want to figure out which drugs work, and avoid wasting time, money, and effort on those that don't, we have to set up properly designed studies.
Belgique Dernières Nouvelles, Belgique Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
La source: BusinessInsider - 🏆 729. / 51 Lire la suite »
La source: BusinessInsider - 🏆 729. / 51 Lire la suite »
La source: BusinessInsider - 🏆 729. / 51 Lire la suite »